Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System

• Autor(a) principal: Elisa Neide Barbosa de Souza
• Data de Publicação: 2022
• Outros Autores: Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Edna Afonso Reis, Juliana Alvares Teodoro, Francisco de Assis Acurcio, Alessandra Maciel Almeida
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: http://dx.doi.org/10.31744/einstein_journal/2022ao6453; http://hdl.handle.net/1843/60532; https://orcid.org/0000-0003-3083-5431; https://orcid.org/0000-0003-2550-7249; https://orcid.org/0000-0002-5528-0658; https://orcid.org/0000-0003-1465-9167; https://orcid.org/0000-0002-0210-0721; https://orcid.org/0000-0002-5880-5261; https://orcid.org/0000-0003-0138-9401
• topic: Effectiveness; Arthritis, rheumatoid; Arthritis, psoriatic; Spondylitis, ankylosing; Biological products; Unified Health System; Rheumatic diseases; Efetividade; Artrite reumatoide; Artrite psoriásica; Espondilite anquilosante; Produtos biológicos; Sistema Único de Saúde; Doenças reumáticas

Objective: To evaluate the therapeutic response (functionality) and its associated factors in patients on biological drugs on the Public Health System for treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Methods: An open prospective cohort was carried out from 2011 to 2019, in Belo Horizonte (MG). Functionality was assessed using the Health Assessment Questionnaire Disability-Index at baseline, and after 6 and 12 months of follow-up. Factors associated with poor functionality were identified through logistic regression. Results: The median Health Assessment Questionnaire Disability-Index at baseline was 1.5 (interquartile range of 0.8-1.9), with poor functionality observed in patients with rheumatoid arthritis. Improved functionality was seen at 6 months of treatment for the three diseases. The predictors of poor functionality at 6 months for psoriatic arthritis and ankylosing spondylitis were female sex, low education levels, and high disease activity; and for rheumatoid arthritis and psoriatic arthritis were female sex, advanced age, and high disease activity. In 12 months, the three diseases had predictors of worse functionality: female sex, low education, and high disease activity. Conclusion: There was a significant improvement in functionality during the follow-up, with better response at 6 months of treatment. Poor functionality was observed in older, female patients, with low education and high disease activity.